

Coagulation and ischaemic stroke



Wolfram Doehner, PD, PhD

Center for Stroke Research Berlin
& Department of Cardiology,
Campus Virchow
Charité – Universitätsmedizin Berlin, Germany


Conflict of Interest

Research support:	EU-FP7, HORIZON-2020, German Ministry of Education and Research, SANOFI, Vifor Pharma,
Consulting	Amgen, Bristol-Myers Squib, Pfizer, Sphingotec, Solartium Dietetics, Stealth Peptides, Boehringer Ingelheim
Speakers Honoraria	Nutricia, SANOFI, Vifor Pharma,

Aetiology of Stroke


85 %

Ischaemic stroke




Embolus

Plaque rupture



15%


Haemorrhagic stroke




Vessel
rupture



Aetiology of Stroke - TOAST classification




Physiologic Coagulation Cascade



Basic coagulation principles - Virchow trias

Rudolf Virchow, Berlin, Charite, 1845



Basic coagulation principles

Virchow Trias

1. Rheology

- Stasis of blood flow
- no laminar flow/ turbulences

2. Hypercoagulability

- activated coagulation factors
- Activated inflammation
- cytokines


3. Endothelial injury

- surface damage
- endothelial dysfunction

= Pro-thrombotic state

Cardiovascular embolus formation


- Rheology
- Hypercoagulability
- Endothelial injury



- **Atrial fibrillation (AF)**
- Reduced LV contractility = CHF
- Recent MI (<4 weeks)
- Regional LV akinesis
- Aneurysm of the LV
- Cardiomyopathy
- Infective Endocarditis
- Rheumatic valve disease
- Heart valve replacement
- overt foramen ovale (permissive)
- Atrial Myxoma

Cardiac causes leading to cardioembolic stroke

AF is the most common cause of cardioembolic stroke




Biomarkers of coagulation - what can we measure ?

	Thrombogenic feature	assessment
Lab	Coagulation factors	D-dimer
		Thrombin-anti-thrombin complex
		Plaminoge activating prot.Fibrine metabolites
		Plasmin activating inhibitor
		P-selectin
		β-Thomboglobulin
	Endothelium dysfunction	V-Willebrand factor
		Soluble Thrombomodulin
		E-electin
Echo	LV dysfunction	LVEF ↓
		Global contractility
		Hypo/Akinesia
		Aneurysma
ECG	Atrial fibrillation	LVEF
		Thrombocyte aggregation
clinical	Comorbidities / risk factors	Scores (CHA ₂ DS ₂ –VASc)

CHF: High risk of cardiac thrombembolism even in maintained sinus rhythm

CHF = Increase ventricle size + Reduced contractility



Spontaneous echocardiographic contrast

- **low blood flow**
- **Hypercoagulability**
- **Endothelial injury**

= Pro-thrombotic state

Rudolf Virchow, Berlin, Charite, 1845

Echo predictors for increased risk of stroke ?

Echocardiographic measurement

validated ?

- Reduced LVEF (<40%)
- enlarged LV size
- low LV blood flow (spontaneous contrast)
- reduced regional contractility
- Aneurysm
- enlarged LA size [1]
- reduced LAA flow
- Tei Index

+++

“Increased risk”
but
no validated
numeric marker

[1] Yaghi S et al. Stroke 2015

Echocardiography – which type for what?

Trans-thoracic echo [TTE]

long distance

lower resolution

no definite exclusion of thrombus

TTE

Left ventricular thrombus

Left ventricular function

Large vegetation

Large tumors

Patent foramen ovale

Atrial septal aneurysm

LVAD associated thrombus

trans-esophageal echo [TEE]

short distance

very high resolution

definite exclusion of thrombus

TEE

Left atrial appendage thrombus

Small vegetation (particularly associated with prosthetic valves)

Abscess

Small tumors

Small patent foramen ovale and morphology

Atrial septal aneurysm morphology

Spontaneous echo contrast

Valvular strands

Aortic arch atheroma

LVAD associated thrombus

Clinical risk factors for embolic stroke

CHA₂DS₂ VASc scores - only in the context of AF related risk

Risk factor	Score
Cardiac failure	1
Hypertension	1
Age >75 years	2
Diabetes mellitus	1
Stroke or TIA	2
Vascular disease	1
Age 65-74	1
Sex category (female)	1

Score: 0 ➡ no anticoagulation
 1 ➡ oral anticoagulation should be considered (IIaB)
 ≥2 ➡ oral anticoagulation (IA)


new 2016
No aspirin at all

Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm

Shunichi Homma, M.D., John L.P. Thompson, Ph.D., Patrick M. Pullicino, M.D.,
et al.

The NEW ENGLAND JOURNAL of MEDICINE 2012

- 2002 - 2010
- N=2305, systol CHF + sinus rhythm
- mean FU 3.5y



HFA Consensus statement

- No benefit of warfarin
- No reason to use warfarin routinely in HF with sinus rhythm

Lip G. et al EHJ 2012

Take home - Stroke as a cardiovascular disease

- ▶ Coagulation = principle mechanism in all ischaemic strokes
- ▶ The trias ...
 - **low blood flow**
 - **Hypercoagulability**
 - **Endothelial injury** ...is involved in **every cardiovascular pathology**
- ▶ No good (quantitative) biomarker available. Qualitative: CHA₂DS₂ –VASc
- ▶ Anticoagulation is highly effective to prevent ischaemic stroke
- ▶▶ Need for further studies / evidence on anticoagulation strategies
 - novel OAC
 - specific cardiovascular pathologies beyond AF

➔ **Call for cardiologists to address stroke prevention**



ESC Council on Stroke:

up-coming agenda

- Board elections June 18
- Cardiovascular round table Mar 18
- Webinars from Apr 18
- Joint scientific sessions
ESOC May 18
ESC Aug 18
EANS Oct 18
- Next workshop "ESC Heart & Stroke"
Jan 2019

THANK YOU

wolfram.doehner@charite.de



Council on Stroke

Nucleus

Events

Membership

ESC COUNCIL ON STROKE

The Council on Stroke


While effective treatment of acute myocardial infarction substantially improved the outcomes of the vast majority of patients during the last 10-15 years, acute stroke remains a major threat with high mortality and/or permanent disability. The incidence of acute stroke is similar to the incidence of acute coronary syndromes, but the outcomes of stroke patients are significantly worse. The rising body of evidence shows, that at least 30-50% (probably even more – this depends on the diagnostic approach) of ischemic strokes are caused by the heart disease (atrial fibrillation,

<https://www.escardio.org/Councils/Council-on-Stroke>

CV involvement in Stroke - the need for joined efforts

CV Risk profile

- **Atrial fibrillation**
- **Hypertension**
- Atherosclerosis
- Myocardial infarction
- Myocarditis
- Endocarditis
- LV Aneurysm
- Chronic heart failure
- Valvular disease
- Valve replacement
- Overt foramen ovale



Post Stroke CV Complication

- “All of the above”
(secondary prevention)

- Cardiopulm. function
- Arrhythmias
- inadequate RR regulation
- Cardiac / vascular re-embolism
- Myocardial Infarction
- CHF exacerbation
- Thrombosis

Cardiac cause of death after stroke

Stroke = high risk for subsequent cardiovascular death

